Stockscreener 앱 받기
46.34
2.17%
-1.03
시간 외 거래:
46.88
0.54
+1.17%
Gsk Plc Adr 주식(GSK)의 최신 뉴스
SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSK - GlobeNewswire Inc.
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
GSK PLC Share Price: What to Know Before the London Market Opens on 17 November 2025 - ts2.tech
The Best Healthcare Stock to Hold in Uncertain Times - Finviz
Looking Into GSK PLC's Recent Short Interest - Sahm
3 Dividend Stocks for November 2025 - Morningstar
10 Best Value Stocks to Buy for the Long Term - Morningstar
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Analysts - MarketBeat
Arkadios Wealth Advisors Acquires 6,734 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR Plans Quarterly Dividend of $0.42 (NYSE:GSK) - MarketBeat
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View - TradingView
GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026 - Sahm
Here's Why GSK (GSK) is a Strong Growth Stock - Yahoo Finance
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
Whittier Trust Co. Sells 5,805 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Forecast & Price Targets: Today, Tomorrow, Next Week - Traders Union
GSK plc Sponsored ADR (GSK) Stock Price Prediction for 2025, 2026, 2030-2040 - Traders Union
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - Sahm
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK) - The Globe and Mail
GSK PLC Sponsored ADR $GSK Shares Acquired by Ethic Inc. - MarketBeat
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce - Sahm
Stanley Laman Group Ltd. Decreases Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment - Sahm
The Best Healthcare Stocks to Buy - Morningstar
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm
Rep. Val T. Hoyle Sells GSK PLC Sponsored ADR (NYSE:GSK) Stock - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy - The Globe and Mail
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why GSK (GSK) is a Top Value Stock for the Long-Term - sharewise.com
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
Park Place Capital Corp Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Bought by Farther Finance Advisors LLC - Defense World
GlaxoSmithKline (GSK) Gets a Hold from Barclays - The Globe and Mail
Sound Income Strategies LLC Has $16.56 Million Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Clean Yield Group - MarketBeat
The 10 Best Companies to Invest in Now - Morningstar
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm
TD Private Client Wealth LLC Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Pneumococcal Vaccine Market Opportunities and Strategies to 2034 - GlobeNewswire Inc.
Miller Howard Investments Inc. NY Purchases 13,023 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - The Globe and Mail
2.19%
0.70%
자본화:
|
볼륨(24시간):